A Proof of Concept Study of the Efficacy and Safety of Oral LAT8881 in Acute Migraine

Summary

This is a randomised, placebo controlled, double blind, crossover proof of concept study to investigate the efficacy and safety of oral LAT8881 in acute migraine, with or without aura.

Timeline

Start

2019-09-24

Primary completion

2020-02-15

Completion

2020-04-10

Outcome

Missed primary endpoint

registry analysis (superiority test); Active vs Placebo; p = 0.9733; Mean Difference (Net) -0.02 (95% CI -1.23 to 1.19) NCT04153409 ↗

Drugs

Indications